TAVR is highly valuable according to Wayne, take that for what it is worth.
if Cardiocell can't make it, not sure why TAVR would. AHZ already have an apparently amazing product but that isn't helping. Why not joint venture with that? Or royalties? Hopefully for AHZ TAVR 1) works 2) is superior to others and 3) they find a big player who wants to use it. None of those are certain.
I mean, if you were a really big player and were keen, it would be cheaper to take it over.
Ann: Appendix 4C - quarterly, page-138
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.10 |
Change
-0.810(8.17%) |
Mkt cap ! $192.3M | |||
| Open | High | Low | Value | Volume |
| $9.50 | $9.77 | $9.01 | $212.2K | 22.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 298 | $9.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.85 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |